Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis.
about
Spatio-temporal simulation of first pass drug perfusion in the liverDevelopment of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly IndividualsConcomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling.Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage AdjustmentsApplication of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients.Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development.The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development.Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working GroupPrediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modellingA physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flowsDose selection based on physiologically based pharmacokinetic (PBPK) approaches.Changes in cytochrome P450s-mediated drug clearance in patients with hepatocellular carcinoma in vitro and in vivo: a bottom-up approach.Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban.Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.An update on computational oral absorption simulation.Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?Use of physiologically based pharmacokinetic modeling for assessment of drug-drug interactions.Physiologically based pharmacokinetic (PBPK) modeling in children.Individualization of drug therapy: history, present state, and opportunities for the future.Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach.Some considerations on the predictions of pharmacokinetic alterations in subjects with liver disease.Physiologically based pharmacokinetic and pharmacodynamic modeling in cancer drug development: status, potential and gaps.Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions.Physiologically Based Pharmacokinetic (Pbpk) Model of the Cyp2d6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions.In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling.Gestation-Specific Changes in the Anatomy and Physiology of Healthy Pregnant Women: An Extended Repository of Model Parameters for Physiologically Based Pharmacokinetic Modeling in Pregnancy.An introduction to physiologically-based pharmacokinetic models.Development of a Physiologically Based Pharmacokinetic Modelling Approach to Predict the Pharmacokinetics of Vancomycin in Critically Ill Septic Patients.Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters.Optimizing the Clinical Use of Carvedilol in Liver Cirrhosis Using a Physiologically Based Pharmacokinetic Modeling Approach.Application of PBPK modelling in drug discovery and development at Pfizer.Have physiologically-based pharmacokinetic models delivered?Gene Expression Patterns Associated With Histopathology in Toxic Liver Fibrosis.Development of a physiologically based pharmacokinetic/pharmacodynamic model to identify mechanisms contributing to entacapone low bioavailability.A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child-Pugh Classification.Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model.Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification.Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development.A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks.
P2860
Q27322901-ADC600C4-06B2-4776-A5F0-7B6302EBF0C7Q30828459-736C5CF8-241E-4C8D-9209-BE7264BAFC01Q33756964-B7079A1A-90CF-4881-B8FB-38F6E026AAB9Q33763177-A993B59B-2ACD-4C87-8D47-4E087D4ADCC5Q34099766-F067B72E-74C2-4113-9B1E-9F418BFC1739Q35054518-87344672-CB90-4228-9679-9BE2139D7F9AQ35560052-807ADEDF-47B8-4397-81AA-729FF91322D7Q35667919-4D71E7AF-CC95-4896-ADBD-BE36B58629FFQ35718576-AA69DECE-28AF-4056-8832-8DFEA574CB67Q36025902-D2A34F1F-906D-4FE1-AEC1-8C0E6AC8C0CEQ36910606-DFE1F0D1-5F8E-4C9B-9672-C4AD1421DD3AQ37317619-0FC4A1AE-7F42-4B24-B7B6-47A138CB1D9CQ37470692-A1B03083-55AF-495E-A95F-190D1CDCF7E0Q37824590-C487A6E2-25DD-40B3-A073-4129D4D0C82DQ37937047-58A2DB09-E4FD-42CF-B6E5-A9D0E5A484A5Q37974113-BC1014E4-190C-4391-B397-6AABBC3258A8Q37998136-E4B72EBA-0562-4D8B-9F29-9E0197C6DBB9Q38016332-C9AA418C-7A07-477E-AC06-383CC86911D9Q38040697-1286CF44-31B3-48C2-84E8-482C7090F46EQ38087695-623C1579-A2EC-4A0C-9428-9C21790E55A5Q38248974-29E384AA-7CFF-4CA5-8369-EE21C3BF5D5EQ38458340-9A0E1BC5-D3E9-4FC1-8C55-A39E24476EDDQ38547705-A81BAF94-AE52-4B0D-9C6A-CB891BD84C9EQ38599220-FE9868B0-6B1C-417A-BB65-E202415C76FBQ38765921-AC181113-65AB-45E7-9287-0C26F65623CDQ38808391-80CE7ECE-B604-43A0-AD46-56A392EBF9D8Q38841163-3BEF16AD-61DE-4FA7-BDE2-23CC1C8AB8FAQ38934455-274DD24E-936E-468F-87FD-0C679ED79148Q39048274-15FD818A-CE7E-4D3C-95AC-F05DE6C30D01Q39183375-91E02E6E-6C65-42F9-9696-369F6A70E46FQ39676474-54B19B3C-A2B3-43EF-8C16-A7160A70676BQ39692575-318EE536-C346-481B-AD84-0B29C1D87646Q39728369-C747A293-255C-4217-BDD6-1A78C70DB8B7Q40512525-6074F6E7-9E21-4EBB-A373-65626DBA46D0Q40619709-1EC1E515-02FE-4BF2-9471-CE3F72447B64Q40839485-69A0B0E5-8C9D-4147-B6D2-A5125AEA029BQ41582110-39BC6FFF-2B8E-40F4-A6B1-DBCFCABA3FBDQ41692388-B8FFAB65-9CF2-46BB-AE28-CD446516DA4BQ41768726-D143F00E-4DBD-4FCF-888C-3D9712EAB921Q42018625-1BFB3903-4A65-4FAC-968F-81084673D964
P2860
Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Physiology-based simulations o ...... patients with liver cirrhosis.
@en
Physiology-based simulations o ...... patients with liver cirrhosis.
@nl
type
label
Physiology-based simulations o ...... patients with liver cirrhosis.
@en
Physiology-based simulations o ...... patients with liver cirrhosis.
@nl
prefLabel
Physiology-based simulations o ...... patients with liver cirrhosis.
@en
Physiology-based simulations o ...... patients with liver cirrhosis.
@nl
P2860
P1476
Physiology-based simulations o ...... patients with liver cirrhosis.
@en
P2093
Andrea N Edginton
Stefan Willmann
P2860
P304
P356
10.2165/00003088-200847110-00005
P577
2008-01-01T00:00:00Z
P6179
1028480959